Current Report Filing (8-k)
March 06 2017 - 5:52AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
Current
Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 6, 2017
Seattle Genetics, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
0-32405
|
|
91-1874389
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
21823 30
th
Drive SE
Bothell, Washington 98021
(Address of principal executive offices, including zip code)
(425)
527-4000
(Registrants telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 8.01 Other Events.
On March 6, 2017, Seattle Genetics, Inc. (the Company) issued a press release announcing the lifting of a clinical hold on phase 1 trials of
vadastuximab talirine
(SGN-CD33A)
in acute myeloid leukemia. The Companys press release is attached as Exhibit 99.1 to this current report and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits.
99.1
|
Press Release of Seattle Genetics, Inc. dated March 6, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SEATTLE GENETICS, INC.
|
|
|
|
|
Date: March 6, 2017
|
|
|
|
By:
|
|
/s/ Clay B. Siegall
|
|
|
|
|
|
|
Clay B. Siegall
|
|
|
|
|
|
|
President and Chief Executive Officer
|
INDEX TO EXHIBITS
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release of Seattle Genetics, Inc. dated March 6, 2017
|
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From May 2023 to May 2024